Pulling SEC filings + quote and writing the call…

Zentalis Pharmaceuticals, Inc.
Next earnings Aug 4, 2026 · consensus $-0.48 EPS
Last earnings +3.4% on 2026-05-12
Conservative balance sheet (liabilities/equity 0.34x); but revenue fell -100.0% YoY.
Zentalis Pharmaceuticals, Inc. shows $0.00 in FY2025 revenue (-100.0% YoY), and -63.4% ROE.
Sources: SEC EDGAR (CIK 0001725160, latest 10-Q filed 2026-05-12) · EODHD · as of 6/25/2026, 2:18:01 AM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.
The risks, catalysts, 12-month price target and the cited SEC figures behind this rating — with Pro.
Unlock with Pro€15/mo · cancel anytime
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | $0.00 | $0.00 | $67.4M | $0.00 |
| Gross profit | — | — | — | — | — |
| Operating income | -$217M | -$227M | -$300M | -$191M | -$153M |
| Net income | -$159M | -$237M | -$292M | -$166M | -$137M |
| Diluted EPS | -$3.72 | -$4.48 | -$4.47 | -$2.33 | -$1.91 |
| Net margin | — | — | — | -246.0% | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
1079 tracked peers · median
Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.
Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.
| 2026-06-16 | Johnson David Michael Director | Award | 57.1K | |
| 2026-06-16 | Skvarka Jan Director | Award | 57.1K | |
| 2026-06-16 | Walker Luke Nathaniel Director | Award | 57.1K | |
| 2026-06-16 | Kariuki Enoch Director | Award | 57.1K | |
| 2026-06-16 | Myers Scott Dunseth Director | Award | 57.1K | |
| 2026-05-26 | Campbell Shannon Director | Award | 114K | |
| 2026-02-10 | Vultaggio Vincent PAO and PFO | Sell | 6.89K @ $2.42 | $16.7K |
| 2026-02-09 | Bruns Ingmar Chief Medical Officer | Sell | 335.00 @ $2.39 | $801.62 |
| 2026-02-09 | Vultaggio Vincent PAO and PFO | Sell | 3.38K @ $2.39 | $8.09K |
| 2026-02-06 | Bruns Ingmar Chief Medical Officer | Sell | 2.96K @ $2.43 | $7.20K |
| 2026-02-06 | Vultaggio Vincent PAO and PFO | Sell | 30.0K @ $2.43 | $72.8K |